Patent ID: 8492530
Filing Date: 2013-07-23
Classification: A61K,A61P,C07K,C12N,G01N

Abstract:
1. A fusion protein comprising at least one unstructured recombinant polypeptide (URP) and a heterologous protein, wherein the heterologous protein is a pharmaceutically active protein selected from the group consisting of cytokines, growth factors, enzymes, receptors, microproteins, hormones, toxins, and hirudin, wherein the fusion protein exhibits an increased serum half-life as compared to the heterologous protein lacking said URP, and wherein the at least one URP is characterized in that: (a) it comprises at least 40 contiguous amino acids; (b) the sum of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues contained in the URP constitutes more than 80% of the total amino acids of the URP, and the remainder, when present, consists of Arginine or Lysine, and the remainder does not contain methionine, cysteine, asparagine, and glutamine; (c) the URP comprises at least three different types of amino acids selected from the group consisting of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P), wherein one of said at least three different types is glycine (G) or glutamine (E); (d) at least 50% of the at least 40 contiguous amino acids in said at least one URP sequence are devoid of secondary structure as determined by Chou-Fasman algorithm; and (e) the URP has a Tepitope score less than −5.